Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

ARCT - Arcturus Therapeutics Holdings Inc.... | Finranks

Home

/

ARCT

A

Arcturus Therapeutics Holdings Inc. (ARCT)

NGM – Real vaqt narxi. Valyuta: USD

7.73

+0.21 (2.81%)

Bozor ochiq: Aug 12, 2026, 3:08 PM EDT

7.47

-0.05 (-0.66%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline

Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.

Arcturus Therapeutics Q2 Earnings Call Highlights

Arcturus Therapeutics Q2 Earnings Call Highlights

Arcturus Therapeutics NASDAQ: ARCT reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform following the end of its collaboration with CSL Seqirus.

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. “We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States,.

Videolar

No Data

There is no data to display

Press-relizlar

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced its financial results for the quarter ended June 30, 2026, and provided corporate updates. “We are encouraged by the continued progress of our ARCT-032 Phase 2 cystic fibrosis study, with active screening and ongoing enrollment across sites in the United States,.